share_log

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Benzinga ·  Dec 11 22:41  · Ratings

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment